R2D2 trial: deprescribing anticholinergics may shield aging brains
NCT ID NCT04270474
First seen May 02, 2026 · Last updated Jun 23, 2026 · Updated 15 times
Summary
This study tests whether a pharmacist-led program to stop certain medications (anticholinergics) can lower dementia risk in older adults. 344 participants aged 65+ who take these drugs will be followed for 2 years, comparing cognitive changes and quality of life between those who deprescribe and those who continue usual care. The goal is to see if reducing these medications improves thinking and memory.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DEMENTIA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Locations
-
Community Health Network Foundation, Inc.
Indianapolis, Indiana, 46256, United States
-
Indiana University Health
Indianapolis, Indiana, 46202, United States
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
deprescribing of anticholinergic medications
What this could lead to
If successful, this could show that stopping certain medications reduces dementia risk and improves cognitive function in older adults.
What could go wrong
This is a relatively small, early-stage trial (344 participants) focused on a specific medication class. Results may not apply to all older adults, and deprescribing may not significantly impact cognition.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.